Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes

Annals of Oncology

Volumn 27, Issue 7, 2016, Pages 1317-1323

  Cheah, C Y ^a,b,c   Chihara, D ^a   Horowitz, S ^a   Sevin, A ^a   Oki, Y ^a   Zhou, S ^a   Fowler, N H ^a   Romaguera, J E ^a   Turturro, F ^a   Hagemeister, F B ^a   Fayad, L E ^a   Wang, M ^a   Neelapu, S S ^a   Nastoupil, L J ^a   Westin, J R ^a   Rodriguez, M A ^a   Samaniego, F ^a   Anderlini, P ^a   Nieto, Y ^a   Fanale, Michelle A ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

Antibody drug conjugates; Brentuximab vedotin; Hodgkin lymphoma; Outcomes research; Retrospective studies; Treatment

Indexed keywords

ALBUMIN; BENDAMUSTINE; BRENTUXIMAB VEDOTIN; GEMCITABINE; ANTIBODY CONJUGATE; DEOXYCYTIDINE;

ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER STAGING; CLASSICAL HODGKIN LYMPHOMA; DRUG EFFECT; DRUG RESPONSE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL TIME; TREATMENT DURATION; TREATMENT OUTCOME; ADOLESCENT; ANALOGS AND DERIVATIVES; DISEASE EXACERBATION; DISEASE FREE SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; HODGKIN DISEASE; MIDDLE AGED; MORTALITY; PATHOLOGY; VERY ELDERLY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BENDAMUSTINE HYDROCHLORIDE; DEOXYCYTIDINE; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOCONJUGATES; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 84977139248     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdw169     Document Type: Article

References (23)

1. Connors JM. Risk assessment in the management of newly diagnosed classical Hodgkin lymphoma. Blood 2015; 125: 1693-1702.
2. Schmitz N, Pfistner B, Sextro M et al. Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359: 2065-2071.
3. Linch DC, Winfield D, Goldstone AH et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial. Lancet 1993; 341: 1051-1054.
4. Arai S, Fanale M, DeVos S et al. Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant. Leuk Lymphoma 2013; 54: 2531-2533.
5. Bartlett NL, Niedzwiecki D, Johnson JL et al. Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. Ann Oncol 2007; 18: 1071-1079.
6. Clozel T, Deau B, Benet C et al. Pegylated liposomal doxorubicin: an efficient treatment in patients with Hodgkin lymphoma relapsing after high dose therapy and stem cell transplantation. Br J Haematol 2013; 162: 846-848.
7. Fanale MA, Forero-Torres A, Rosenblatt JD et al. A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies. Clin Cancer Res 2012; 18: 248-255.
8. Francisco JA, Cerveny CG, Meyer DL et al. cAC10-vcMMAE, an anti-CD30- monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood 2003; 102: 1458-1465.
9. Younes A, Gopal AK, Smith SE et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin's lymphoma. J Clin Oncol 2012; 30: 2183-2189.
10. Gopal AK, Ramchandren R, O'Connor OA et al. Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation. Blood 2012; 120: 560-568.
11. Moskowitz CH, Nademanee A, Masszi T et al. Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2015; 385: 1853-1862.
12. Cheson BD, Fisher RI, Barrington SF et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 2014; 32: 3059-3068.
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
14. Andersen P, Gill R. Cox's regression model for counting processes, a large sample study. Ann Stat 1982; 10: 1100-1120.
15. Zinzani PL, Vitolo U, Viviani S et al. Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory Hodgkin's lymphoma: experience with 27 patients. Clin Lymphoma Myeloma Leuk 2015; 15: 404-408.
16. Czyz A, Romejko-Jarosinska J, Knopinska-Posluszny W et al. Treatment strategy based on gemcitabine-containing salvage chemotherapy used with intent to proceed to second stem cell transplant for patients with Hodgkin lymphoma relapsing after a prior autologous transplant. Leuk Lymphoma 2013; 54: 973-978.
17. Hawkes EA, Barton S, Cunningham D et al. GEM-P chemotherapy is active in the treatment of relapsed Hodgkin lymphoma. Ann Hematol 2014; 93: 827-834.
18. Ansell SM, Lesokhin AM, Borrello I et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med 2015; 372: 311-319.
19. Ansell S, Armand P, Timmerman JM et al. Nivolumab in patients ( pts) with relapsed or refractory classical hodgkin lymphoma (R/R cHL): clinical outcomes from extended follow-up of a phase 1 study (CA209-039). Blood 2015; 126: 583.
20. Armand P, Shipp MA, Ribrag V et al. PD-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure: safety, efficacy, and biomarker assessment. Blood 2015; 126: 584.
21. Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998; 339: 1506-1514.
22. Chen R, Hou J, Newman E et al. CD30 downregulation, MMAE resistance, and MDR1 upregulation are all associated with resistance to brentuximab vedotin. Mol Cancer Ther 2015; 14: 1376-1384.
23. Palanca-Wessels MC, Czuczman M, Salles G et al. Safety and activity of the anti- CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory Bcell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol 2015; 16: 704-715.